论文部分内容阅读
Induction of cytochrome P450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis. CYP3A is of key importance in human drug metabolism, being involved in presystemic extraction of more than 50% of all drugs currently available and of various endogenous compounds. The refore, we compared the induction potential of UDCA with that of the prototypica l inducer rifampicin in a human model study with the CYP3A substrates budesonide and cortisol. Twelve patients with early- stage primary biliary cirrhosis and eight healthy volunteers were treated with UDCA (15 mg/kg daily) for 3 weeks and subsequently with rifampicin (600 mg/d) for 1 week. Extensive pharmacokinetic p rofiling of oral budesonide (3 mg) was performed by determination of budesonide and phase I metabolites (6β - hydroxybudesonide, 16α - hydroxyprednisolone) in plasma and urine at baseline and at the end of each treatment. In parallel, u rinary 6β - hydroxycortisol, a validated marker of CYP3A induction, was determ ined. UDCA did not affect biotransformation of budesonide and urinary excretion of 6α - hydroxycortisol either in patients or in healthy volunteers. Ratios of areas under plasma concentration- time curves (AUC0- 12h during UDCA/AUC0- 1 2h before UDCA) of both metabolites were not higher than those of budesonide its elf. In contrast, administration of rifampicin markedly induced CYP3A metabolism , resulting in abolished budesonide plasma levels and high urinary excretion of 6β - hydroxycortisol. Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC16α - hydroxyprednisolone/ AUCbudesonide in patients: basel ine, 8.6 ± 3.9; UDCA, 10.7 ± 7.1; rifampicin, 527.0 ± 248.7). In conclusio n, UDCA is not a relevant inducer of CYP3A enzymes in humans.
Induction of cytochrome P450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis. CYP3A is of key importance in human drug metabolism, being involved in presystemic extraction of more than 50% of all drugs currently available and of various endogenous compounds. The refore, we compared the induction potential of UDCA with that of the prototypica l inducer rifampicin in a human model study with the CYP3A substrates budesonide and cortisol. Twelve patients with early- stage primary biliary cirrhosis and eight healthy volunteers were treated with UDCA (15 mg / kg daily) for 3 weeks and followed with rifampicin (600 mg / d) for 1 week. Extensive pharmacokinetic rofiling of oral budesonide (3 mg) was performed by determination of budesonide and phase I metabolites 6β - hydroxybudesonide, 16α - hydroxyprednisolone) in plasma and urine at baseline and at the end of each treatment. In parallel, u rinary 6β - hydroxycortisol, a validated ma Rake of CYP3A induction, was determined. UDCA did not affect biotransformation of budesonide and urinary excretion of 6α-hydroxycortisol either in patients or in healthy volunteers. Ratios of areas under plasma concentration-time curves (AUC0-12h during UDCA / AUC0-1 2h before UDCA) of both metabolites were not higher than those of budesonide its elf. In contrast, administration of rifampicin markedly induced CYP3A metabolism, resulting in abolished budesonide plasma levels and high urinary excretion of 6β-hydroxycortisol. Metabolite formation was enhanced by rifampicin, but not by UDCA (eg, AUC16α-hydroxyprednisolone / AUCbudesonide in patients: basel ine, 8.6 ± 3.9; UDCA, 10.7 ± 7.1; rifampicin, 527.0 ± 248.7). In conclusio n, UDCA is not a relevant inducer of CYP3A enzymes in humans .